Drug intelligence / Profile preview

anatabine

Development stage
Phase 1
Lead developer
Rock Creek Pharmaceuticals
Modality
Small Molecules
Administration
Oral, Topical
01

Overview

**Anatabine** is a minor bipyridine alkaloid found in plants of the Solanaceae family, including tobacco, tomato, eggplant, and pepper. Structurally related to nicotine, anatabine acts primarily as a **nicotinic acetylcholine receptor agonist** and exhibits significant **anti-inflammatory activity**. Its anti-inflammatory effects are mediated by inhibition of STAT3 and NF-κB signaling, reduction of pro-inflammatory cytokines (TNFα, IL-6), and activation of the NRF2 and MAPK pathways. Anatabine crosses the blood-brain barrier and was developed as both a dietary supplement (Anatabloc, CigRx) and topical cosmetic for inflammatory conditions including rosacea and joint pain. It was researched for potential therapeutic use in Alzheimer's disease, Hashimoto's thyroiditis, multiple sclerosis, and intestinal inflammation. Commercial development was discontinued after regulatory and financial setbacks.

Brand names
AnatablocCigRx
Other names
(-)-anatabine(S)-anatabine3-[(2S)-1,2,3,6-tetrahydropyridin-2-yl]pyridine(S)-1,2,3,6-tetrahydro-2,3'-bipyridinebipyridine alkaloid(±)-anatabine(R)-(+)-anatabine1,2,3,6-tetrahydro-2,3'-bipyridine
02

Targets

α4β2 nAChR (Nicotinic acetylcholine receptor alpha4 beta2 subtype)CHRNA7 (α7 nicotinic receptor)

Beyond the preview

Go deeper on anatabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anatabine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call